Circulating Tumor Cells in Metastatic Breast Cancer: Clinical Applications and Future Possibilities
Circulating tumor cells (CTCs) have gained importance as an emerging biomarker in solid tumors in the last two decades. Several detection assays have been introduced by various study groups, with EpCAM-based CellSearch system being the most widely used and standardized technique. In breast cancer, d...
Main Authors: | , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-05-01
|
Series: | Applied Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-3417/10/9/3311 |
id |
doaj-69f07aba0a53438aa677fef47094ef0e |
---|---|
record_format |
Article |
spelling |
doaj-69f07aba0a53438aa677fef47094ef0e2020-11-25T02:11:39ZengMDPI AGApplied Sciences2076-34172020-05-01103311331110.3390/app10093311Circulating Tumor Cells in Metastatic Breast Cancer: Clinical Applications and Future PossibilitiesMaggie Banys-Paluchowski0Florian Reinhardt1Tanja Fehm2Department of Gynecology, Asklepios Klinik Hamburg-Barmbek, 22307 Hamburg, GermanyDepartment of Obstetrics and Gynecology, University of Düsseldorf, 40225 Düsseldorf, GermanyDepartment of Obstetrics and Gynecology, University of Düsseldorf, 40225 Düsseldorf, GermanyCirculating tumor cells (CTCs) have gained importance as an emerging biomarker in solid tumors in the last two decades. Several detection assays have been introduced by various study groups, with EpCAM-based CellSearch system being the most widely used and standardized technique. In breast cancer, detection of CTCs correlates with clinical outcome in early and metastatic settings. CTC persistence beyond first cycle of palliative chemotherapy indicates poor response to treatment in metastatic situation. Beyond prognostication and therapy monitoring, CTC counts can guide treatment decisions in hormone receptor positive HER2-negative metastatic breast cancer. Furthermore, CTC-based therapy interventions are currently under investigation in clinical trials. In this review, we focus on the current state of knowledge and possible clinical applications of CTC diagnostics in patients with metastatic breast cancer.https://www.mdpi.com/2076-3417/10/9/3311breast cancerliquid biopsycirculating tumor cellsurvivaltargeted therapy |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Maggie Banys-Paluchowski Florian Reinhardt Tanja Fehm |
spellingShingle |
Maggie Banys-Paluchowski Florian Reinhardt Tanja Fehm Circulating Tumor Cells in Metastatic Breast Cancer: Clinical Applications and Future Possibilities Applied Sciences breast cancer liquid biopsy circulating tumor cell survival targeted therapy |
author_facet |
Maggie Banys-Paluchowski Florian Reinhardt Tanja Fehm |
author_sort |
Maggie Banys-Paluchowski |
title |
Circulating Tumor Cells in Metastatic Breast Cancer: Clinical Applications and Future Possibilities |
title_short |
Circulating Tumor Cells in Metastatic Breast Cancer: Clinical Applications and Future Possibilities |
title_full |
Circulating Tumor Cells in Metastatic Breast Cancer: Clinical Applications and Future Possibilities |
title_fullStr |
Circulating Tumor Cells in Metastatic Breast Cancer: Clinical Applications and Future Possibilities |
title_full_unstemmed |
Circulating Tumor Cells in Metastatic Breast Cancer: Clinical Applications and Future Possibilities |
title_sort |
circulating tumor cells in metastatic breast cancer: clinical applications and future possibilities |
publisher |
MDPI AG |
series |
Applied Sciences |
issn |
2076-3417 |
publishDate |
2020-05-01 |
description |
Circulating tumor cells (CTCs) have gained importance as an emerging biomarker in solid tumors in the last two decades. Several detection assays have been introduced by various study groups, with EpCAM-based CellSearch system being the most widely used and standardized technique. In breast cancer, detection of CTCs correlates with clinical outcome in early and metastatic settings. CTC persistence beyond first cycle of palliative chemotherapy indicates poor response to treatment in metastatic situation. Beyond prognostication and therapy monitoring, CTC counts can guide treatment decisions in hormone receptor positive HER2-negative metastatic breast cancer. Furthermore, CTC-based therapy interventions are currently under investigation in clinical trials. In this review, we focus on the current state of knowledge and possible clinical applications of CTC diagnostics in patients with metastatic breast cancer. |
topic |
breast cancer liquid biopsy circulating tumor cell survival targeted therapy |
url |
https://www.mdpi.com/2076-3417/10/9/3311 |
work_keys_str_mv |
AT maggiebanyspaluchowski circulatingtumorcellsinmetastaticbreastcancerclinicalapplicationsandfuturepossibilities AT florianreinhardt circulatingtumorcellsinmetastaticbreastcancerclinicalapplicationsandfuturepossibilities AT tanjafehm circulatingtumorcellsinmetastaticbreastcancerclinicalapplicationsandfuturepossibilities |
_version_ |
1724913481294020608 |